Keyphrases
Melanoma
89%
Sentinel Lymph Node Biopsy
43%
United States
39%
Soft Tissue Sarcoma
27%
Gastrointestinal Stromal Tumor
25%
Tumor
20%
Resection
20%
Head-and-neck
19%
Sentinel Lymph Node
19%
Early Detection
16%
Metastatic Melanoma
16%
Completion Lymph Node Dissection
15%
Wide Local Excision
14%
Clinical Practice Guidelines
14%
Oncology
13%
Gene Therapy
13%
Imatinib
13%
Adjuvant Therapy
13%
Melanoma Patients
12%
Surgeons
12%
NCCN Guidelines
12%
Single Institution
12%
Patient Management
12%
Imaging Studies
11%
National Cancer Database
11%
Tumor Burden
11%
31-gene Expression Profile
11%
Metastatic Tumor
11%
Overall Survival
10%
Surveillance Imaging
10%
Routine Imaging
10%
Imaging-guided
10%
Dermatofibrosarcoma Protuberans
10%
Minimally Invasive
10%
Social Vulnerability
10%
Neoadjuvant Therapy
9%
Hazard Ratio
9%
Breast Cancer
9%
Sarcoma
8%
Node-positive
8%
Gene Expression Profile
8%
Lymph Node Positive
8%
Practice Patterns
8%
Oncological Outcomes
8%
Surgical Outcomes
8%
Ionizing Radiation
7%
Gastric Gastrointestinal Stromal Tumor
7%
Pancreaticoduodenectomy
7%
Pancreatic Cancer
7%
Recurrence Risk
7%
Medicine and Dentistry
Melanoma
100%
Neoplasm
48%
Sentinel Lymph Node Biopsy
40%
Gastrointestinal Stromal Tumor
32%
Soft Tissue Sarcoma
29%
Recurrent Disease
29%
Metastatic Carcinoma
28%
Malignant Neoplasm
26%
Retroperitoneal Lymph Node Dissection
24%
Neck
19%
Diseases
17%
Lymph Node
15%
Sentinel Lymph Node
15%
Cancer
14%
Gene Expression
14%
Melanoma Skin Cancer
13%
Wide Local Excision
13%
Adenocarcinoma
12%
Surgeon
12%
Pancreas Cancer
12%
Sentinel Node
11%
Overall Survival
10%
Imatinib
10%
Adjuvant Therapy
10%
Oncology
10%
Dermatofibrosarcoma Protuberans
10%
Gene Therapy
10%
Primary Tumor
9%
Connective Tissue Cancer
8%
Carcinoid
7%
Breast Cancer
7%
Neoadjuvant Therapy
6%
Gene Expression Profiling
6%
Randomized Clinical Trial
6%
Inguinal Lymph Node
6%
Radiation Response
6%
Pediatrics
6%
Health Care Cost
6%
Radiation Therapy
6%
Lymph Node Metastasis
6%
Base
6%
Hazard Ratio
6%
Distant Metastasis
5%
Sunitinib
5%
Mitosis Rate
5%
Pancreaticoduodenectomy
5%
Surgical Margin
5%
Limb Tumor
5%
Self Examination
5%
Targeted Therapy
5%